David Borg

Medicin och livsvetenskap

1. Adenocarcinoma 100%
2. Stomach 70%
3. podocalyxin 38%
4. Neoplasms 35%
5. Survival 34%
6. human ERBB2 protein 30%
7. Biomarkers 28%
8. Esophageal Neoplasms 26%
9. Stomach Neoplasms 24%
10. Drug Therapy 24%
11. Chemoradiotherapy 19%
12. B-Lymphocytes 19%
13. Plasma Cells 16%
14. Proteins 16%
15. Pancreatic Neoplasms 15%
16. Junctional Adhesion Molecule A 14%
17. Macrophages 13%
18. Recurrence 13%
19. DNA Mismatch Repair 12%
20. Capecitabine 12%
21. Deglutition Disorders 11%
22. Neoadjuvant Therapy 11%
23. T-Lymphocytes 11%
24. Tumor-Infiltrating Lymphocytes 10%
25. Death Domain Receptors 10%
26. Tumor Microenvironment 9%
27. ErbB Receptors 9%
28. Machine Learning 9%
29. gemcitabine 9%
30. Radiotherapy 9%
31. Lymphocyte Activation 8%
32. Mutation Rate 8%
33. Rectal Neoplasms 8%
34. Neoplasm Metastasis 8%
35. Therapeutics 8%
36. Immunotherapy 8%
37. Cell Count 7%
38. Natural Killer Cells 7%
39. Interferons 7%
40. Lymph Nodes 7%
41. Mutation 7%
42. Immunohistochemistry 6%
43. Ligands 5%
44. Clinical Studies 5%
45. Gene Expression 5%
46. Confidence Intervals 5%